Cerebrolysin is a mixture of small peptides and free amino acids made from porcine brain proteins and supplied as an injectable solution. It has been studied in people after stroke and in dementia, as well as in animal experiments on cell survival and repair. The clinical findings vary with the setting: a rehabilitation trial found better arm-and-hand task performance, while the large CASTA acute-stroke trial did not establish its planned overall benefit. Those findings, the mixture’s identity and uncertainty about serious unwanted events are central to understanding the product.
Overview
The name identifies a manufactured multicomponent preparation. A small synthetic peptide has a defined sequence; Cerebrolysin has no one sequence or molecular mass that describes all its constituents. The manufacturer’s abbreviated Austrian product information lists an aqueous concentrate, with sodium hydroxide and water for injection as excipients. Its concentration describes the mass of the mixture; individual active constituents are not quantified by that label value.
Molecular profile
- Preparation
- Porcine-brain-derived mixture of low-molecular-weight peptides and free amino acids Source
- Product form
- Cerebrolysin solution for injection; manufacturer’s abbreviated Austrian information lists aqueous concentrate Source
- Labeled concentrate
- 215.2 mg of Cerebrolysin concentrate per mL; this is mixture mass, not the amount of one active peptide Source
- Excipients in cited product
- Sodium hydroxide and water for injection Source
- Sequence, formula and molecular mass
- No single sequence, molecular formula or molecular mass describes this multicomponent preparation Source
Forms and derivatives
Cerebrolysin solution for injection
The branded mixture and manufacture define the material tested in its clinical trials. The manufacturer’s abbreviated Austrian information identifies the concentrate and excipients.
Other animal-brain peptide mixtures
Cortexin and other named mixtures are not alternate sequences or generic chemical names for Cerebrolysin. The Cochrane review includes a similar agent in some pooled analyses, while its reported serious-event analysis is specifically Cerebrolysin.
That distinction matters for interpreting both chemistry and clinical results. Heiss and colleagues (2012) describe a porcine-brain-derived preparation of low-molecular-weight peptides and amino acids. Trial findings apply to the manufactured Cerebrolysin preparation and clinical setting studied. Some systematic reviews combine Cerebrolysin and a separately named similar agent for selected outcomes; the products still need to be distinguished when an estimate is interpreted.
Uses and research areas
The major clinical questions concern function after neurological disease. Acute-stroke trials have asked whether adding Cerebrolysin to existing treatment improves neurological impairment, disability or daily activities. Rehabilitation trials have examined recovery of arm and hand movement while participants also receive structured therapy. Dementia studies instead measure cognitive test performance and clinicians’ overall impressions of change, sometimes incorporating caregiver observations.
These outcomes are related but answer different questions. An arm test can improve without proving a change in memory or survival. A cognitive-test score can improve without establishing delayed disease progression or lasting independence. The Alzheimer and vascular-dementia trials also enrolled different conditions. The diagnosis, treatment setting and outcome determine what each result means. Muresanu et al. (2016), CARS, Alvarez et al. (2006) and Guekht et al. (2011) provide examples of these distinct settings.
Mechanism of action
The mixture has been investigated for effects resembling those of proteins that support nerve-cell survival and development. Its constituents and the identity of the components responsible for a particular effect are less straightforward than a single ligand binding one receptor. Animal experiments have measured several responses, including neural precursor-cell activity after stroke.
Zhang and colleagues (2010) studied rats after an embolus blocked a middle cerebral artery. Compared with rats given the injection preparation without Cerebrolysin, treated rats had more staining for dividing neural precursor cells and migrating immature neurons near the injured region 28 days later. These are cells and markers involved in generating new nerve cells. Cultured precursor-cell experiments also found more proliferation, and inhibiting PI3K/Akt signaling abolished that increase. The pathway is an intracellular system that can regulate survival and growth.
The same report helps separate repair-related observations from acute tissue rescue. Selected behavioral measurements improved at 21 and 28 days, but the cited delayed-treatment conditions did not establish a smaller infarct, the area of dead tissue caused by lost blood supply. More precursor-cell staining and better rat behavior cannot establish that new functional human circuits formed, identify every active constituent, or explain a clinical benefit on their own.
Pharmacokinetics
A pharmacokinetic study follows a defined substance in the body over time. With Cerebrolysin, the measurement would first need to identify a particular constituent or validated marker. The clinical outcome reports reviewed here do not provide one human blood concentration curve, absorption estimate or elimination half-life that represents the entire mixture. The labeled mass of concentrate does not solve this analytical problem.
The stroke and dementia trials administered the preparation intravenously and followed clinical outcomes over weeks or months. A result measured at day 90 or week 24 is an outcome follow-up time, not evidence that active constituents remained in blood or brain for that long. The reviewed trials also do not quantify how much of a specified peptide reached the human brain. Claims about prolonged effects need to remain separate from measured exposure.
Research findings
CASTA did not establish its planned overall stroke benefit
The CASTA trial by Heiss and colleagues (2012) enrolled 1,070 people with acute ischemic hemispheric stroke: 529 were assigned Cerebrolysin and 541 saline. Treatment began within 12 hours, alongside aspirin, and participants were followed to day 90. The planned primary assessment combined three scales covering disability, daily activities and neurological deficits. The planned comparison did not establish an overall recovery benefit.
A post hoc analysis, chosen after examining the data, suggested a more favorable result among participants with more severe initial strokes. Its uncertainty and exploratory selection mean it cannot replace the main trial result. It is a possible question for a further trial with that population specified in advance.
Rehabilitation-focused CARS found better arm-and-hand performance
The CARS trial by Muresanu and colleagues (2016) enrolled 208 people and began study treatment 24–72 hours after stroke. Both groups received a standardized rehabilitation program for 21 days; one also received Cerebrolysin and the other saline. The Cerebrolysin group improved more from baseline to day 90 on the Action Research Arm Test, which scores grasping, gripping, pinching and larger arm movements. The Mann–Whitney estimate was 0.71 (95% confidence interval 0.63–0.79). This summarizes the chance that a randomly selected treated participant’s improvement ranks above a randomly selected control participant’s improvement, with tied changes shared equally; 0.5 indicates no tendency for either group to improve more. The estimate compares changes in scores; it does not describe the proportion of people who recovered.
CARS centered on a particular rehabilitation program and arm outcome, whereas CASTA tested a broader acute-stroke assessment. Their populations, timing and outcomes differ. Manufacturer support and the modest sample also matter when assessing reproducibility and less common harms.
An add-on thrombolysis trial did not improve day-90 disability
Lang et al. (2013) randomized 119 patients receiving alteplase, a clot-dissolving medicine, to additional Cerebrolysin or placebo. The sequential trial stopped after its third interim analysis because Cerebrolysin had not shown a benefit on disability at day 90, measured with the modified Rankin Scale. Earlier neurological responder analyses favored Cerebrolysin, but they were secondary outcomes and do not establish the planned later disability benefit. The original abstract reported no group difference in adverse events; it does not exclude uncommon harms.
Dementia findings depend on the diagnosis and outcome
In the Alvarez et al. (2006) Alzheimer trial, people with mild to moderate disease were assigned one of three Cerebrolysin amounts or placebo. The study followed them for 24 weeks, including a period after the treatment course ended. At week 24, the group receiving the lowest tested amount had better scores than placebo on the modified Alzheimer’s Disease Assessment Scale cognitive test; the higher two did not establish a cognitive-test benefit, although all active groups improved the overall clinical rating. Of 279 randomized participants, 269 received treatment, 251 entered the reported efficacy analysis and 237 completed the study. Those different denominators matter when judging missing data and generalizing the estimates.
The Guekht et al. (2011) vascular-dementia trial tested two treatment cycles alongside background aspirin. At 24 weeks, cognitive-test scores improved by 10.6 points with Cerebrolysin and 4.4 points with placebo; the adjusted difference in score change was −6.17 points, favoring Cerebrolysin because lower ADAS-cog+ scores indicate fewer measured cognitive problems. Clinician/caregiver ratings also favored the active treatment. This is a finding in vascular dementia over six months. It does not demonstrate prevention of dementia, a permanent effect after treatment, or the same benefit in people with a different cause of cognitive difficulty.
Safety and tolerability
Several individual trials reported similar overall adverse-event frequencies between groups. A careful assessment also needs the type and severity of events. The 2023 Cochrane review found that the total serious-event comparison remained uncertain: risk ratio 1.16, 95% confidence interval 0.81–1.66, in three trials with 1,335 participants. Serious events that did not cause death occurred in 20 of 667 Cerebrolysin participants (3.0%) and 8 of 668 placebo participants (1.2%); the pooled risk ratio was 2.39 (95% confidence interval 1.10–5.23). A serious event can involve hospitalization, a threat to life or substantial disability; occurrence during a trial does not by itself prove drug causation. The review also did not establish a mortality benefit from adding the treatment after acute ischemic stroke.
The manufacturer’s abbreviated Austrian information lists hypersensitivity to a component, epilepsy and severe renal impairment as contraindications. That page states that prescribing information varies between countries. Its current U.S. notice says Cerebrolysin is not registered with FDA and is not approved for sale or distribution in the United States. Country-specific authorization and safety evidence are separate questions: use in a country does not erase uncertain trial results or apply its label to a different preparation.
What the research means
Cerebrolysin has been studied in several randomized human trials. The useful findings concern defined clinical settings, particularly arm recovery during structured early rehabilitation and cognitive-test changes in selected dementia populations. The largest acute-stroke trial’s unsuccessful primary comparison and the serious-event signal prevent a simple claim of established general neurological benefit or broad safety.
The complex composition leaves further analytical questions. A cell pathway, a trial infusion, a blood concentration and a daily-life outcome describe different parts of the investigation. More work is needed to identify relevant constituents, reproduce clinical findings in well-defined populations and clarify longer-term benefits and harms. A validated exposure marker would help connect the preparation to biological and clinical effects.
FAQs
Is Cerebrolysin one peptide?
It is a porcine-brain-derived mixture of peptides and free amino acids. The preparation cannot be represented by one amino-acid sequence, formula or molecular mass. The concentrate mass on the product information is not the amount of a single active molecule. Heiss et al. (2012), CASTA, EVER product information
Did the largest stroke trial find a benefit?
CASTA randomized 1,070 people soon after ischemic stroke. Its planned combined assessment of disability, daily activities and neurological deficits did not establish a difference between Cerebrolysin and saline. A more favorable observation among people with more severe strokes came from a post hoc analysis and needs confirmation. Heiss et al. (2012), CASTA
What was favorable in the rehabilitation trial?
In CARS, both groups received a structured rehabilitation program. People assigned Cerebrolysin improved more from baseline to day 90 on the Action Research Arm Test, which scores tasks requiring arm and hand movement, than people assigned saline. The trial enrolled 208 people and tested early post-stroke rehabilitation; it does not establish general cognitive enhancement. Muresanu et al. (2016), CARS
Does the Alzheimer trial show that more product works better?
The 279-person dose-ranging trial found a cognitive-test difference at 24 weeks with the lowest tested amount. The higher two amounts improved the global clinical rating but did not establish a cognitive-test improvement. The pattern does not support a simple more-is-better claim, and it does not demonstrate prevention or reversal of the disease. Alvarez et al. (2006)
Is Cerebrolysin FDA-approved?
The manufacturer’s current U.S. notice states that Cerebrolysin is not registered with FDA and is not approved for sale or distribution in the United States. The same page provides abbreviated prescribing information based on the Austrian product information and cautions that national information varies. EVER product information
Do similar overall adverse-event rates establish safety?
Overall event counts can conceal clinically different events. The 2023 Cochrane review found the total serious-event comparison uncertain but a higher rate of serious events that did not cause death with Cerebrolysin. The manufacturer lists allergy to a component, epilepsy and severe renal impairment as contraindications in its abbreviated Austrian information. Ziganshina et al. (2023), EVER product information
How long does Cerebrolysin remain in the blood?
The clinical outcome studies reviewed here do not provide a validated human concentration curve or one elimination half-life for the mixture. A useful exposure study would need to specify which constituents or markers were measured. Duration of a reported rehabilitation or cognitive effect cannot substitute for a concentration measurement. Heiss et al. (2012), CASTA, Muresanu et al. (2016), CARS, Alvarez et al. (2006)
Comparisons and related reading
References
The 1,070-person acute-stroke trial did not establish improvement on its planned combined disability, daily-activity and neurological outcome. More favorable severity-subgroup observations were exploratory.
In early stroke rehabilitation, patients receiving Cerebrolysin did better on a structured arm-and-hand task assessment at day 90 than those receiving saline. Both groups received the same rehabilitation program.
A separate randomized add-on trial with clot-dissolving treatment did not establish better disability outcomes at 90 days. Its primary design differs from rehabilitation-focused CARS.
The four-group Alzheimer trial found a cognitive-test difference at the lowest tested amount and global clinical differences across active groups. Higher amounts did not establish greater cognitive benefit.
The 242-person vascular-dementia trial reported larger cognitive-test improvements and better clinician/caregiver ratings at 24 weeks with Cerebrolysin plus background treatment than with placebo plus background treatment.
After experimental stroke in rats, Cerebrolysin increased markers of dividing precursor cells and immature neurons and improved selected behavioral measurements. Infarct volume did not show a demonstrated reduction in the cited treatment conditions.
The independent review found no established mortality benefit and a potential increase in serious events that did not cause death. Its serious-event analysis specifically concerns Cerebrolysin; some other analyses also included Cortexin.
The manufacturer identifies the injectable concentrate, excipients and Austrian prescribing context, including contraindications. Its U.S. notice states that Cerebrolysin is not FDA-registered or approved for sale or distribution.
Glossary
- Ischemic stroke
- Brain injury caused by loss of blood supply, usually from a blocked artery.
- Action Research Arm Test
- A scored assessment of grasping, gripping, pinching and larger arm movements used after stroke; higher scores indicate better task performance.
- Modified Rankin Scale
- A scale describing disability and dependence after stroke, ranging from no symptoms to death.
- ADAS-cog+
- An extended test battery measuring cognitive problems in dementia studies; a lower score generally means fewer measured problems.
- CIBIC+
- A clinician’s rating of change based on interviews and caregiver information, used to judge overall clinical change.
- Serious adverse event
- An unwanted medical event involving consequences such as death, a threat to life, hospitalization or substantial disability; occurrence does not by itself prove that a study drug caused it.